首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Discovery of heterocyclic replacements for the coumarin core of anti-tubercular FadD32 inhibitors
Authors:Chao Fang  Katie K Lee  Raymond Nietupski  Robert H Bates  Raquel Fernandez-Menendez  Eva Maria Lopez-Roman  Laura Guijarro-Lopez  Yunxing Yin  Zuozhong Peng  James E Gomez  Stewart Fisher  David Barros-Aguirre  Brian K Hubbard  Michael H Serrano-Wu  Deborah T Hung
Institution:1. The Broad Institute of MIT and Harvard, 415 Main St, Cambridge, MA 02142, USA;2. Department of Molecular Biology and Center for Integrative and Computational Biology, Massachusetts General Hospital, 185 Cambridge St, Boston, MA 02114, USA;3. Department of Genetics, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115, USA;4. Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, 28760 Madrid, Spain;5. WuXi AppTec, 168 Nanhai Rd, Tianjin Economic-Technological Development Area (TEDA), Tianjin 300457, China;6. WuXi AppTec, 288 Fute Zhong Rd, Waigaoqiao Free Trade Zone, Shanghai 200131, China
Abstract:Previous work established a coumarin scaffold as a starting point for inhibition of Mycobacterium tuberculosis (Mtb) FadD32 enzymatic activity. After further profiling of the coumarin inhibitor 4 revealed chemical instability, we discovered that a quinoline ring circumvented this instability and had the advantage of offering additional substitution vectors to further optimize. Ensuing SAR studies gave rise to quinoline-2-carboxamides with potent anti-tubercular activity. Further optimization of ADME/PK properties culminated in 21b that exhibited compelling in vivo efficacy in a mouse model of Mtb infection.
Keywords:(minimum inhibitory concentration for 90%)  (Mycobacterium tuberculosis)  CFU  (colony-forming unit)  (effective dose for 99% CFU count reduction)  mLM  (mouse liver microsome)  hLM  (human liver microsome)  95% CI  (95% confidence interval)  Mycobacterium tuberculosis  FadD32 inhibitor  Structure-activity relationship  Quinoline-2-carboxamide  In vivo efficacy
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号